Understanding the beneficial role of glucagon-like peptide-1 (GLP-1) for normalizing intestinal lipoprotein metabolism during insulin resistance

了解胰高血糖素样肽 1 (GLP-1) 在胰岛素抵抗期间使肠道脂蛋白代谢正常化的有益作用

• 批准号: 255025
• 负责人: Farr Sarah L
• 金额: $ 1.27万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-02-01 至 2013-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=255025&lang=en
• 关键词: Apob48; Chylomicron Collection; Dpp-Iv Inhibitor; Dyslipidemia; Glucagon-Like Peptide-1; Intracerebroventricular Injection; Postprandial Lipoproteins; Small Intestine; Syrian Golden Hamster Model; Type 2 Diabetes

Type 2 diabetes has been labelled a world-wide epidemic, with 285 million individuals currently affected; a number that is expected to reach 439 million by the year 2030. Though this condition is known for causing high blood sugar levels, abnormalities in

2型糖尿病已被标记为世界范围的流行病，目前有2.85亿人受影响;预计到2030年，这一数字将达到4.39亿。虽然这种情况是已知的导致高血糖水平，异常，